Laura Teschner Joins Headlands Research as Chief People Officer

Teschner brings two decades of experience in high-growth organizations to support the clinical research site network’s rapid expansion

San Francisco, CA, May 18, 2023—Headlands Research, a leading multinational network of clinical trial sites, today announced the appointment of Laura Teschner as its Chief People Officer (CPO). A vital component of the company’s wider strategy, Laura’s position represents the growth of the clinical research site network and staff to support more clinical trials and provide access to investigative therapies to a more diverse, representative population.  

As we magnify our therapeutic and geographic reach through the expansion of our research network, it’s important that we bolster the Headlands Research team by adding this key role,” said Cathy Collins, CEO of Headlands Research. “Laura’s history of building out human resources (HR) functionality in high-growth healthcare companies makes her the perfect addition to an already stellar leadership team.” 

Laura has 20 years of HR experience in roles with increasing leadership responsibility, primarily in healthcare and biotechnology. She has led HR teams in private equity-backed organizations experiencing rapid growth both organically and via mergers and acquisitions. Most recently, Laura served as CPO for Managed Markets Insight & Technology (MMIT), a healthcare data technology company. Prior to this, Laura was the Senior Vice President of HR at K2M, a medical device company developing spinal implants, where she was a key member of the acquisition and integration of K2M by Stryker. Laura has a BS in Finance from Virginia Tech and an MBA from Marymount University.

I’m driven by the ability to provide a positive impact, so I’m grateful for the opportunity to join a company whose mission is to improve lives,” said Laura. “I look forward to growing the HR capacity to provide employees with behind-the-scenes support to help drive their innovation in developing life-saving therapies.”

Headlands Research’s scaling of its internal operations reflects the site network’s rapid expansion, with the recent addition of three sites and more in the pipeline. The launch of the de novo site Headlands Research Detroit serves multiple therapeutic areas, including Alzheimer’s disease and vaccines. The acquisition of established sites Headlands Research Eastern Massachusetts, which specializes in neurodegenerative diseases such as Alzheimer’s disease, and Clinvest, which specializes in chronic diseases including migraine and arthritis, further expands the site network’s capabilities and access to a large, diverse participant population. 

To learn more about Headlands Research and its extensive network of research sites, visit, contact, or follow the company on LinkedIn.